Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
(2010) In Modern Pathology 23(5). p.686-693- Abstract
- Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-beta and AKT pathways. To determine whether protein kinase C-beta expression has prognostic significance for diffuse large B-cell lymphoma patients treated with immunochemotherapy, we analyzed the expression of protein kinase C-beta II, BCL-2 and cell of origin immunohistochemically from pretreatment samples of 95 diffuse large B-cell lymphoma patients. All patients received rituximab with CHOP or CHOEP. According to Kaplan-Meier analyses, overall survival at 3 years was better among the patients with low than high protein kinase C-beta II protein levels... (More)
- Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-beta and AKT pathways. To determine whether protein kinase C-beta expression has prognostic significance for diffuse large B-cell lymphoma patients treated with immunochemotherapy, we analyzed the expression of protein kinase C-beta II, BCL-2 and cell of origin immunohistochemically from pretreatment samples of 95 diffuse large B-cell lymphoma patients. All patients received rituximab with CHOP or CHOEP. According to Kaplan-Meier analyses, overall survival at 3 years was better among the patients with low than high protein kinase C-beta II protein levels (94 vs 76%, P = 0.036). The prognostic value of protein kinase C-beta II expression on survival was seen in the patients with low and high International Prognostic Index risk groups, and in all molecular entities. Gene expression data from an independent set of 233 diffuse large B-cell lymphoma patients treated with a combination of rituximab and CHOP-like chemotherapy was analyzed in comparison. Accordingly, a better 3-year overall survival was observed among the subgroup with low protein kinase C-beta II mRNA levels (84 vs 68%, P = 0.005). In multivariate analysis with cell of origin, protein kinase C-beta II mRNA expression remained as an independent predictor for overall survival. Together, the data show that protein kinase C-beta II expression has prognostic significance in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Modern Pathology (2010) 23, 686-693; doi: 10.1038/modpathol.2010.43; published online 26 February 2010 (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1619346
- author
- Riihijarvi, Sari ; Koivula, Satu ; Nyman, Heidi ; Fjordén, Karin LU ; Jerkeman, Mats LU and Leppa, Sirpa
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- prognosis, protein kinase C-beta II, diffuse large B-cell lymphoma, R-CHOP
- in
- Modern Pathology
- volume
- 23
- issue
- 5
- pages
- 686 - 693
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000277252900007
- scopus:77952011772
- pmid:20190733
- ISSN
- 1530-0285
- DOI
- 10.1038/modpathol.2010.43
- language
- English
- LU publication?
- yes
- id
- 5eaea554-47a2-48bc-99d8-669129e4be0c (old id 1619346)
- date added to LUP
- 2016-04-01 10:00:39
- date last changed
- 2022-01-25 18:54:54
@article{5eaea554-47a2-48bc-99d8-669129e4be0c,
abstract = {{Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-beta and AKT pathways. To determine whether protein kinase C-beta expression has prognostic significance for diffuse large B-cell lymphoma patients treated with immunochemotherapy, we analyzed the expression of protein kinase C-beta II, BCL-2 and cell of origin immunohistochemically from pretreatment samples of 95 diffuse large B-cell lymphoma patients. All patients received rituximab with CHOP or CHOEP. According to Kaplan-Meier analyses, overall survival at 3 years was better among the patients with low than high protein kinase C-beta II protein levels (94 vs 76%, P = 0.036). The prognostic value of protein kinase C-beta II expression on survival was seen in the patients with low and high International Prognostic Index risk groups, and in all molecular entities. Gene expression data from an independent set of 233 diffuse large B-cell lymphoma patients treated with a combination of rituximab and CHOP-like chemotherapy was analyzed in comparison. Accordingly, a better 3-year overall survival was observed among the subgroup with low protein kinase C-beta II mRNA levels (84 vs 68%, P = 0.005). In multivariate analysis with cell of origin, protein kinase C-beta II mRNA expression remained as an independent predictor for overall survival. Together, the data show that protein kinase C-beta II expression has prognostic significance in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Modern Pathology (2010) 23, 686-693; doi: 10.1038/modpathol.2010.43; published online 26 February 2010}},
author = {{Riihijarvi, Sari and Koivula, Satu and Nyman, Heidi and Fjordén, Karin and Jerkeman, Mats and Leppa, Sirpa}},
issn = {{1530-0285}},
keywords = {{prognosis; protein kinase C-beta II; diffuse large B-cell lymphoma; R-CHOP}},
language = {{eng}},
number = {{5}},
pages = {{686--693}},
publisher = {{Nature Publishing Group}},
series = {{Modern Pathology}},
title = {{Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients}},
url = {{http://dx.doi.org/10.1038/modpathol.2010.43}},
doi = {{10.1038/modpathol.2010.43}},
volume = {{23}},
year = {{2010}},
}